title: A Case of Metastatic Adamantinoma That Responded Well to Sunitinib.
abstract: Adamantinoma is a rare low-grade malignant bone tumor of epithelial origin. Metastatic adamantinoma has been reported to be resistant to chemotherapy. We report a case of metastatic adamantinoma to the lung, 10 years after the initial diagnosis of tibial mass. The patient received radiation therapy to the lung with partial response. A surveillance PET scan revealed progression of the lung mass and biopsy confirmed to be progressive residual metastatic adamantinoma. He received carboplatin and etoposide for 7 months and achieved a partial response. Four months later, PET scan showed disease progression. We started him on sunitinib, a multikinase inhibitor. He achieved a good partial response for 3 years. He died due to pneumonia at the age of 72.
authors.affiliation: Hematology and Oncology, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA.
authors.forename: Andrew D
authors.identifier: 0000-0002-8448-9266
authors.initials: AD
authors.lastname: Liman
authors.affiliation: Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA.
authors.forename: Agnes K
authors.identifier: 0000-0002-0806-0580
authors.initials: AK
authors.lastname: Liman
authors.affiliation: Pharmacy, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA.
authors.forename: Jenna
authors.initials: J
authors.lastname: Shields
authors.affiliation: Hematology and Oncology, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA.
authors.forename: Becky
authors.identifier: 0000-0002-5459-0865
authors.initials: B
authors.lastname: Englert
authors.affiliation: Radiology, VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA.
authors.forename: Rashmikant
authors.initials: R
authors.lastname: Shah